PRESS RELEASE published on 02/13/2024 at 08:30, 7 months 7 days ago Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and sponsorship of scientific symposium at the 19th Congress of European Crohn’s and Colitis Organization (ECCO) Abivax to present four abstracts on obefazimod for ulcerative colitis at 19th ECCO Congress, including a sponsored symposium on emerging treatment mechanisms. Event details available on ECCO website Abivax Obefazimod Ulcerative Colitis ECCO Congress Scientific Symposium
PRESS RELEASE published on 02/13/2024 at 08:30, 7 months 7 days ago Abivax annonce la présentation de quatre abstracts sur obefazimod dans la rectocolite hémorragique et l’organisation d’un symposium scientifique au 19e congrès de la ECCO Abivax annonce la présentation de quatre abstracts sur obefazimod dans la rectocolite hémorragique et l'organisation d'un symposium scientifique au 19e congrès de la ECCO. Pour plus d'informations, visitez le stand Abivax dans le hall des exposants de l’ECCO Abivax Obefazimod Rectocolite Hémorragique Symposium Scientifique ECCO
PRESS RELEASE published on 02/07/2024 at 08:30, 7 months 13 days ago Abivax appoints Ana Sharma as Vice President, Global Head of Quality Abivax appoints Ana Sharma as Vice President, Global Head of Quality. Ana Sharma brings over 20 years of experience in the biopharmaceutical industry and has a strong track record in quality and GxP compliance Abivax Ana Sharma Biopharmaceutical Industry Quality Compliance GxP
PRESS RELEASE published on 02/07/2024 at 08:30, 7 months 13 days ago Abivax: Ana Sharma est nommée Vice-Présidente,Global Head of Quality d’Abivax Ana Sharma est nommée Vice-Présidente, Global Head of Quality d’Abivax. Elle apporte plus de 20 ans d’expérience dans l’industrie biopharmaceutique et contribuera au programme ABTECT de phase 3 et à la mise sur le marché du médicament obefazimod Abivax Ana Sharma Qualité GxP Traitement Thérapeutique Maladies Inflammatoires Chroniques
PRESS RELEASE published on 02/02/2024 at 08:30, 7 months 18 days ago Abivax annonce une mise à jour de son programme de développement clinique de phase 2b avec obefazimod dans la maladie de Crohn modérément à sévèrement active Abivax annonce une mise à jour de son programme de développement clinique de phase 2b avec obefazimod dans la maladie de Crohn modérément à sévèrement active. L'initiation de l’inclusion des patients est prévue pour le troisième trimestre 2024, les données d'induction à 12 semaines sont attendues au deuxième semestre 2026 Abivax Obefazimod Développement Clinique Maladie De Crohn Phase 2b
PRESS RELEASE published on 02/02/2024 at 08:30, 7 months 18 days ago Abivax announces update to obefazimod Phase 2b clinical development program in moderately to severely active Crohn’s disease Abivax updates obefazimod Phase 2b clinical program in Crohn’s disease following FDA feedback. Trial design modification to align with FDA recommendations. Patient enrollment to start in Q3 2024 Abivax Obefazimod Crohn’s Disease Phase 2b Clinical Trial FDA Feedback
PRESS RELEASE published on 01/29/2024 at 18:00, 7 months 21 days ago ABIVAX: Nombre d’actions composant le capital social et nombre total de droits de vote au 31.12.23. ABIVAX annonce le nombre d'actions et de droits de vote au 31.12.2023 conformément aux réglementations en vigueur. La société est spécialisée en biotechnologie et développe des traitements thérapeutiques pour les maladies inflammatoires chroniques Nombre D'actions Droits De Vote Biotechnologie Abivax Traitements Thérapeutiques
PRESS RELEASE published on 01/29/2024 at 18:00, 7 months 21 days ago ABIVAX: Bilan semestriel du contrat de liquidité au 31 décembre 2023. Bilan semestriel du contrat de liquidité au 31 décembre 2023 pour ABIVAX, publié le 29 janvier 2024 Euronext Paris Bilan Semestriel Abivax Contrat De Liquidit\u00e9 TSAF
PRESS RELEASE published on 01/24/2024 at 08:30, 7 months 27 days ago Abivax to host KOL Investor Event to review phase 2b clinical data and phase 3 trial design for obefazimod in patients with moderately to severely active ulcerative colitis on February 6, 2024 Abivax, a clinical-stage biotechnology company, will host a virtual KOL Investor Event to review phase 2b clinical data and phase 3 trial design for obefazimod in patients with ulcerative colitis on February 6, 2024. The event will feature discussions on the unmet medical need, current treatment landscape, and ongoing clinical development plans for obefazimod. The key speakers at the event will be Marla Dubinsky, MD, and Parambir Dulai, MD, who are both consultants for Abivax and members of the Steering Committee for the IBD Program. Abivax Obefazimod Ulcerative Colitis Clinical Development KOL Investor Event
PRESS RELEASE published on 01/22/2024 at 08:30, 7 months 29 days ago Abivax provides 2024 strategic outlook and lays out key milestones over next 12 months Abivax, a clinical-stage biotechnology company, provides its 2024 strategic outlook and key milestones, including the expected data read-outs and trial results for its lead drug candidate obefazimod in the treatment of ulcerative colitis and Crohn’s disease. The company also outlines its financial update and objectives for strengthening its product pipeline. Learn more about Abivax's priorities and milestones for 2024. Abivax Obefazimod Ulcerative Colitis Crohn’s Disease Clinical Trials
Published on 09/20/2024 at 09:05, 3 hours 36 minutes ago Nano One Closes on $5 Million Sale of Vacant Land
Published on 09/20/2024 at 02:00, 10 hours 41 minutes ago Academy of Math and Science Celebrates Hispanic Heritage Month
Published on 09/19/2024 at 23:15, 13 hours 26 minutes ago Cypher Metaverse Inc. Announces Second Closing of Financing
Published on 09/19/2024 at 23:00, 13 hours 41 minutes ago WestJet Partners with FLYHT and NOAA to Improve Weather Forecasting in North America
Published on 09/20/2024 at 11:20, 1 hour 21 minutes ago Dalata Hotel Group PLC: HOL-Holding(s) in Company*
Published on 09/20/2024 at 11:14, 1 hour 27 minutes ago EQS-Adhoc: Raiffeisen Bank International AG: RBI signs agreement on the sale of Priorbank JSC to Soven 1 Holding Limited
Published on 09/20/2024 at 09:01, 3 hours 40 minutes ago Original-Research: THE NAGA GROUP AG (von NuWays AG): BUY
Published on 09/20/2024 at 08:45, 3 hours 56 minutes ago BAIKOWSKI : Rapport financier semestriel 2024
Published on 09/20/2024 at 08:00, 4 hours 41 minutes ago MEDESIS PHARMA : Résultats encourageants de la première phase de l’essai clinique de phase 2a pour le traitement de la maladie d’Alzheimer avec le NanoLIthium